Fecal Microbiota Transplantation is Poised for a Makeover
Fecal Microbiota Transplantation is Poised for a Makeover
With multiple microbiota therapeutics in the pipeline for recurrent Clostridium difficile infection, clinicians foresee a shift in treatment options for the condition.
Fecal Microbiota Transplantation is Poised for a Makeover
Fecal Microbiota Transplantation is Poised for a Makeover

With multiple microbiota therapeutics in the pipeline for recurrent Clostridium difficile infection, clinicians foresee a shift in treatment options for the condition.

With multiple microbiota therapeutics in the pipeline for recurrent Clostridium difficile infection, clinicians foresee a shift in treatment options for the condition.

food and drug administration
Pandemic Accelerates Trend Toward Remote Clinical Trials
Pandemic Accelerates Trend Toward Remote Clinical Trials
Jef Akst | May 1, 2021
Now more than ever before, recruiting patients for a research study doesn’t have to mean getting them to leave their homes.
FDA Clears Genetic Modification in Pigs for Biomedicine and Food
FDA Clears Genetic Modification in Pigs for Biomedicine and Food
Catherine Offord | Dec 15, 2020
The decision, which concerns the removal of a sugar molecule on the surface of cells in a line of domestic pigs, marks the first time an approval has been granted for both purposes simultaneously.
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
A Challenge Trial for COVID-19 Would Not Be the First of Its Kind
Jef Akst | Oct 8, 2020
Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.
Doctors Forge Ahead with Plasma for COVID-19, Benefits Uncertain
Doctors Forge Ahead with Plasma for COVID-19, Benefits Uncertain
Shawna Williams | Aug 14, 2020
Researchers say the popularity of convalescent plasma makes it more difficult to gather high-quality data on its efficacy.
Activities Discovered for Some Inactive Drug Ingredients
Activities Discovered for Some Inactive Drug Ingredients
Ruth Williams | Jul 23, 2020
Screens of hundreds of drug excipients reveal that some can interact with biological targets, contradicting their FDA categorization as inert.
Former FDA Commissioner Frank Young Dies
Former FDA Commissioner Frank Young Dies
Jef Akst | Dec 2, 2019
The physician-researcher laid the groundwork for genetic cloning and led the US Food and Drug Administration as the country faced the AIDS crisis in the 1980s.
FDA Approves New Cystic Fibrosis Drug
FDA Approves New Cystic Fibrosis Drug
Shawna Williams | Oct 24, 2019
The treatment, Trikafta, increases lung function in most patients with the disease—but comes with a hefty price tag.
Antidepressant Approvals Could Herald New Era in Psychiatric Drugs
Antidepressant Approvals Could Herald New Era in Psychiatric Drugs
Bianca Nogrady | Oct 1, 2019
The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
First New Tuberculosis Drug Approved in 50 Years
First New Tuberculosis Drug Approved in 50 Years
Jef Akst | Aug 15, 2019
The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.
Survey of Stem Cell Clinics Reveals Cause for Concern
Survey of Stem Cell Clinics Reveals Cause for Concern
Jef Akst | Aug 1, 2019
Two coauthors of a new study discuss their findings about nearly 170 facilities in the southwestern US selling unproven therapies—and what should be done about them.
Sunscreen Ingredients Absorbed into Blood: Study
Sunscreen Ingredients Absorbed into Blood: Study
Catherine Offord | May 7, 2019
FDA researchers report that multiple active ingredients wind up in users’ bloodstream and recommend toxicology testing to investigate the clinical significance of the findings.
FDA Lifts Import Restrictions on Genetically Engineered Salmon
FDA Lifts Import Restrictions on Genetically Engineered Salmon
Catherine Offord | Mar 11, 2019
The fast-growing fish can now be raised and sold in the US, although it’s likely to be some time before the product hits the market.
A Landmark Study On BPA Leaves Scientists at Odds
A Landmark Study On BPA Leaves Scientists at Odds
Shawna Williams | Oct 26, 2018
Conceived as a way to resolve differences between government regulators and academics over the chemical’s effects, the CLARITY-BPA collaboration instead highlights divisions.
Two CAR T-Cell Therapies Greenlighted in Europe
Two CAR T-Cell Therapies Greenlighted in Europe
Jef Akst | Aug 28, 2018
Cancer treatments from Novartis and Gilead earn approval from EU regulators, but a first pass by the UK’s state-funded health service finds CAR T is too expensive. 
Questions Raised About “Breakthrough” Therapies’ Clinical Support
Questions Raised About “Breakthrough” Therapies’ Clinical Support
Catherine Offord | Jul 17, 2018
Compared to other drugs, therapeutics given breakthrough status receive FDA approval on the basis of weaker trial evidence, a study finds.
Supreme Court Nominee Draws Concern from Environmentalists
Supreme Court Nominee Draws Concern from Environmentalists
Catherine Offord | Jul 10, 2018
President Trump’s pick, Judge Brett Kavanaugh, has often opposed court involvement in environmental and health regulations.
Congress Passes “Right to Try” Bill
Congress Passes “Right to Try” Bill
Jim Daley | May 23, 2018
Medical groups have criticized the legislation, which will give terminal patients access to experimental treatments, as dangerous and unnecessary.
FDA Seeks to Block Two Unregulated Stem Cell Clinics
FDA Seeks to Block Two Unregulated Stem Cell Clinics
Jim Daley | May 11, 2018
Two patients became legally blind after receiving treatments at the facilities.